Decarboxylase

Other Names

No alternative names.

Synopsis

Decarboxylases as Dietary Supplement Ingredients: A Comprehensive Reference

1. Identity and Nomenclature

The term "decarboxylase" does not refer to a single substance but rather to a class of enzymes that catalyze the removal of a carboxyl group (–COOH) from amino acids and other organic substrates, releasing carbon dioxide (CO₂) and yielding a structurally simpler amine or compound. Decarboxylase is primarily recognized as a class of enzymes rather than a traditional herbal ingredient; these enzymes facilitate the removal of a carboxyl group from amino acids and other organic compounds, a process essential for synthesizing key neurotransmitters such as dopamine and serotonin.

In the context of dietary supplements, nutrition science, and natural health products, the term encompasses several specific enzymes or substrate-enzyme systems of greatest relevance:

Aromatic L-Amino Acid Decarboxylase (AADC/AAAD), also known as dopa decarboxylase (DDC; EC 4.1.1.28): a pyridoxine-dependent enzyme that catalyzes the decarboxylation of L-DOPA and 5-HTP to produce dopamine and serotonin, respectively.
Glutamate Decarboxylase (GAD; EC 4.1.1.15): a pyridoxal-5'-phosphate-dependent enzyme that catalyzes the irreversible α-decarboxylation of L-glutamic acid to γ-aminobutyric acid (GABA) and CO₂.
Histidine Decarboxylase (HDC; EC 4.1.1.22): an enzyme that transforms histidine into histamine.
Ornithine Decarboxylase (ODC; EC 4.1.1.17): catalyzes the first step in polyamine biosynthesis, converting ornithine to putrescine, which is further metabolized to spermidine and spermine.

All of the major mammalian decarboxylases require pyridoxal 5'-phosphate (PLP), the active form of vitamin B6, as an essential cofactor. Pyridoxal 5'-phosphate, the active form of vitamin B₆, is an essential cofactor for multiple enzymes, including aromatic L-amino acid decarboxylase, which catalyses the final stage in the production of the neurotransmitters dopamine and serotonin. Aromatic L-amino acid decarboxylase is a homodimeric enzyme with a molecular mass of approximately 53 kDa per subunit and requires PLP as a cofactor for its catalytic activity.

Natural Sources and Distribution

Decarboxylase enzymes are not isolated natural ingredients in the conventional botanical sense. Rather, they are endogenous human enzymes whose activity can be influenced by dietary substrates and cofactors, or they are present in microorganisms used in fermented food production. The enzyme is widely distributed in eukaryotes as well as prokaryotes, where it—together with its reaction product GABA—fulfils very different physiological functions.

Key natural sources relevant to supplementation include:

Mucuna pruriens (velvet bean): a plant traditionally used in Ayurvedic medicine that contains a significant amount of L-dopa (4%–6%), the primary active component of conventional levodopa (LD) therapy. The L-dopa in this plant is a direct substrate for AADC.
Lactic acid bacteria (LAB): the occurrence of gad genes encoding GAD has been shown for many microorganisms, and GABA-producing lactic acid bacteria (LAB) have been a focus of research during recent years. A wide range of traditional foods produced by fermentation based on LAB offer the potential of providing new functional food products enriched with GABA that may offer certain health benefits.
Vitamin B6-rich foods: found primarily in vegetables, peanuts, eggs, soy, and cereals, vitamin B6 (pyridoxal, pyridoxamine) appears to play a significant role in neuronal development. Dietary B6 is required to form the PLP cofactor upon which all major decarboxylases depend.
Fermented foods: GABA is found naturally in small amounts in certain foods, particularly fermented foods, where bacterial fermentation produces GABA from glutamate.

Common Forms and Preparations

In the supplement market, decarboxylase-related products are typically positioned not as isolated enzyme supplements but as substrates, cofactors, or products of decarboxylase reactions:

GABA supplements (the enzymatic product of glutamate decarboxylase): produced by bacterial fermentation, often using Lactobacillus hilgardii with glutamate added as a substrate, and trademarked as PharmaGABA (Pharma Foods International, Japan), which is the form used in most clinical trials evaluating stress and sleep outcomes.
Mucuna pruriens seed powder or extract: providing naturally-occurring L-dopa as a decarboxylase substrate.
Vitamin B6 (pyridoxine, pyridoxal, pyridoxal-5'-phosphate) supplements: acting as the essential cofactor for all major amino acid decarboxylase reactions.
5-Hydroxytryptophan (5-HTP): the immediate precursor substrate for serotonin synthesis via AADC.

2. Traditional and Historical Use

Because decarboxylase is an enzymatic concept rather than a discrete plant or mineral, its traditional use is understood through the lens of herbal and food traditions that unknowingly engaged decarboxylase-dependent pathways.

Ayurvedic Medicine — Mucuna pruriens

The seed powder of the leguminous plant Mucuna pruriens has long been used in traditional Ayurvedic Indian medicine for diseases including parkinsonism. In the Ayurvedic system, the plant is known as Kapikachhu or Atmagupta. Traditional preparations involved roasting or boiling the seeds and administering the powder in milk or ghee formulations. The recognized therapeutic targets in traditional Ayurveda included motor diseases, impotence, and nervous system disorders — effects now understood to be at least partially mediated by the plant's high L-dopa content, which is converted to dopamine by AADC in the brain and peripheral tissues. M. pruriens is recognized for its anti-inflammatory, antioxidant, antiapoptotic, and antiparkinsonian properties, which collectively suggest therapeutic benefits for individuals with Parkinson's disease.

Traditional Fermented Foods

Cultures across Asia have long prepared GABA-enriched fermented foods without awareness of the underlying glutamate decarboxylase mechanism. The amount of GABA obtained by enrichment from food is quite low; it is used as a nutritional supplement in products such as GABA-green tea and GABA-brown rice. Japanese, Korean, and Chinese food traditions include fermented soy products, rice wine, miso, and pickled vegetables that are now understood to be significant dietary sources of GABA produced by the action of lactic acid bacteria-derived glutamate decarboxylase. The need to increase food safety and improve human health has led to a worldwide increase in interest in GABA, produced by lactic acid bacteria.

Fermented Fish and Histidine Decarboxylase

The role of histidine decarboxylase has been recognized in the context of fish fermentation practices found across Southeast Asia, the Mediterranean, and coastal Europe. In these traditions, fish were salted and fermented deliberately to produce flavor compounds and biogenic amines; the decarboxylation of histidine can also be related to fermentation processes involved in production of foods such as meat and meat products, wines, alcoholic beverages, sauerkraut, yoghurt and cheese. The relationship between histidine decarboxylase activity and histamine formation was not understood mechanistically until the modern era.

3. Key Constituents and Active Compounds

3.1 Aromatic L-Amino Acid Decarboxylase (AADC) and its Substrates

Aromatic L-amino acid decarboxylase is the enzyme responsible for the decarboxylation step in both the catecholamine and the indolamine synthetic pathways. Immunological and molecular biological studies suggest that it is a single enzyme with one catalytic site but with different locations for attachment of the substrates. The enzyme is widely distributed in the brain and in peripheral tissues.

AADC's main natural substrates are:

L-3,4-dihydroxyphenylalanine (L-DOPA) → dopamine
5-Hydroxytryptophan (5-HTP) → serotonin (5-HT)

In normal dopamine and serotonin neurotransmitter synthesis, AADC is not the rate-limiting step in either reaction. However, AADC becomes the rate-limiting step of dopamine synthesis in patients treated with L-DOPA (such as in Parkinson's disease), and the rate-limiting step of serotonin synthesis in people treated with 5-HTP (such as in mild depression or dysthymia).

Aromatic L-amino acid decarboxylase is an essential enzyme for the formation of catecholamines, indolamines, and trace amines. In humans, AADC is also the rate-limiting enzyme in the formation of trace amines.

3.2 Glutamate Decarboxylase (GAD) and GABA Synthesis

Glutamate decarboxylase (GAD) catalyzes the irreversible decarboxylation of L-glutamate to the valuable food supplement γ-aminobutyric acid (GABA). γ-Aminobutyric acid (GABA), a four-carbon non-essential amino acid that is widely distributed in nature, plays a major role as an inhibitory neurotransmitter in the mammalian central nervous system. GABA has several physiological activities, including diuretic and tranquilizer effects, and has been used in the treatment of epilepsy and the prevention of obesity.

GABA is synthesized from glutamate by glutamate decarboxylase (GAD65), which is also a type 1 diabetes autoantigen. High titers of autoantibodies to glutamic acid decarboxylase (GAD) are well documented in association with stiff person syndrome (SPS).

3.3 Histidine Decarboxylase (HDC) and Histamine

Histamine formed in food results from the decarboxylation of the natural amino acid histidine catalyzed by a specific enzyme, histidine decarboxylase (HDC), present in several kinds of bacteria. Histamine is involved in many pathophysiological and physiological functions, such as gastric acid secretion, inflammation, and the regulation of vasodilation and bronchoconstriction. In the human body, histidine decarboxylase is expressed in mast cells, basophils, the gastric mucosa, and certain neurons, contributing to immune regulation and gastric acid secretion.

3.4 Ornithine Decarboxylase (ODC) and Polyamine Biosynthesis

Ornithine decarboxylase (ODC) is the rate-limiting enzyme in polyamine biosynthesis and involved in the production of putrescine through the decarboxylation of ornithine. Polyamines play different biological roles such as cell motility, cell–cell interactions, stabilization of nucleic acid or membranes, regulation of ion channels and receptors, affecting chromatin structure, cell cycle activities of protein kinases and transcription factors, and affecting translation or transcription.

3.5 The Essential Cofactor: Pyridoxal 5'-Phosphate (PLP/Vitamin B6)

Pyridoxal 5'-phosphate (PLP) is the active form of vitamin B6, which is the essential cofactor for more than 100 metabolic reactions, including enzymes involved in the metabolism of the neurotransmitters glutamate, gamma hydroxybutyric acid (GABA), glycine, D-serine, dopamine, serotonin, and noradrenaline, among other biomolecules. PLP serves as a cofactor for approximately 180 B6-dependent (PLP-dependent) enzymes involved in several essential cellular processes, including racemization, decarboxylation, transamination, elimination, and others, which are responsible for neurotransmitter production, heme biosynthesis, nucleic acid production, sphingomyelin synthesis, and glucose metabolism.

PLP-dependent enzymes are biosynthesized as apo-B6 enzymes and then converted to the catalytically active holo-B6 enzymes by Schiff base formation between the aldehyde of PLP and an active site lysine of the protein. Before addition of the pyridoxal phosphate cofactor, the apoenzyme exists in an open conformation. Upon cofactor binding, a large structural transformation occurs as the subunits pull closer and close the active site.

Pathways reliant on PLP include amino acid and neurotransmitter metabolism, folate and 1-carbon metabolism, protein and polyamine synthesis, carbohydrate and lipid metabolism, mitochondrial function, and erythropoiesis.

4. Mechanisms of Action

4.1 Neurotransmitter Synthesis (AADC Pathway)

The aromatic L-amino acid decarboxylase (AADC) enzyme catalyzes the last step in the biosynthesis of the monoamine neurotransmitters dopamine and serotonin. Dopamine itself is a precursor for the synthesis of epinephrine and norepinephrine. Therefore, the activity of this single enzyme determines the bioavailability of four critical monoamine neurotransmitters.

There is substantial evidence that the activity of AADC in striatum is regulated by activation and induction, and second messengers play a role. Enzyme activity can be modulated by drugs acting on a number of neurotransmitter receptors including dopamine (D1–D4), glutamate (NMDA), serotonin (5-HT1A, 5-HT2A), and nicotinic acetylcholine receptors. Generally, antagonists enhance AADC activity, while agonists may diminish it.

4.2 GABA Production (GAD Pathway)

Pyridoxal phosphate is a cofactor of glutamic acid decarboxylase (GAD), allowing for conversion of glutamate into GABA. This reaction takes place in the cytoplasm of terminals of GABAergic neurons; therefore, vitamin B6 deficiency may cause epileptic seizures in children. The inhibitory action of GABA on postsynaptic neurons underlies its known anxiolytic, antiseizure, and antihypertensive biological activities.

4.3 Vitamin B6 Deficiency and Decarboxylase Function

In two patients with inherited disorders of vitamin B₆ metabolism, reductions in plasma aromatic L-amino acid decarboxylase activity were observed. In one patient, this change was related to an increase in Km for pyridoxal 5'-phosphate. Furthermore, pyridoxal 5'-phosphate-deficient human neuroblastoma cells were found to exhibit reduced levels of AADC activity and protein, but with no alteration in expression. These findings suggest that maintaining adequate pyridoxal 5'-phosphate availability may be important for optimal treatment of aromatic L-amino acid decarboxylase deficiency and L-dopa-responsive conditions.

4.4 Regulation of ODC and Polyamine Synthesis

Ornithine decarboxylase is the most finely tuned enzyme of the polyamine biosynthesis pathway, as it is regulated at different levels: transcriptional, translational, post-translational, and by feedback inhibition. In cancer, this enzyme is overexpressed due to its regulation by the protooncogene c-Myc, and has thus been proposed as a drug target against this disease.

5. Scientific Evidence by Area of Use

5.1 Neurological and Neurodegenerative Disease (AADC / Parkinson's Disease)

The strongest and most clinically validated application of decarboxylase research in nutrition and supplementation concerns the use of AADC substrates (primarily L-dopa from Mucuna pruriens) in Parkinson's disease management.

A landmark double-blind, randomized, controlled crossover clinical trial examined Mucuna pruriens seed powder in Parkinson's disease: eight Parkinson's disease patients with a short duration L-dopa response and on-period dyskinesias completed a randomized, controlled, double-blind crossover trial. Patients were challenged with single doses of 200/50 mg L-dopa/carbidopa (LD/CD), and 15 g and 30 g of mucuna preparation in randomized order at weekly intervals. L-dopa pharmacokinetics were determined, and Unified Parkinson's Disease Rating Scale and tapping speed were obtained at baseline and repeatedly during the 4 hours following drug ingestion.

A 2025 systematic review of clinical trials (published in Parkinson's Disease) synthesized the available evidence: a comprehensive search was conducted in PubMed, Embase, and Web of Science for clinical trials published up to February 2024; out of 466 articles identified, 5 clinical trials involving a total of 108 participants (mean age: 60 years) were included. The overall body of clinical evidence for Mucuna pruriens in Parkinson's disease remains limited by small sample sizes.

Bioavailability consideration: A critical pharmacological distinction between plant-sourced L-dopa and pharmaceutical L-dopa formulations relates to decarboxylase inhibition. AADC is highly relevant in Parkinson's disease, where it acts as the rate-limiting enzyme for converting therapeutically administered L-DOPA to dopamine in the brain. Peripheral inhibition of AADC by drugs such as carbidopa or benserazide is essential to increase central nervous system bioavailability of L-DOPA and reduce peripheral side effects. Standard pharmaceutical L-dopa is administered with a peripheral AADC inhibitor (carbidopa or benserazide), which does not occur when consuming Mucuna pruriens alone. This means AADC freely converts plant-derived L-dopa in the periphery before it can cross the blood-brain barrier.

Evidence strength: Preliminary to moderate. The existing clinical trials are small (N = 8–108), limited in duration, and largely demonstrate comparable efficacy to standard L-dopa therapy at equivalent doses in short-term settings. Larger, longer-term randomized controlled trials are needed. Evidence is insufficient to recommend Mucuna pruriens as a replacement for standard Parkinson's pharmacotherapy.

5.2 AADC Deficiency (Genetic Neurological Disease)

AADC deficiency is a rare autosomal recessive disorder caused by mutations in the DDC gene, leading to disrupted dopamine and serotonin synthesis and resulting in severe developmental delay, movement disorders, and autonomic dysfunction. Deficiency of the AADC enzyme leads to an inability to synthesize dopamine and serotonin from their precursors, L-3,4-dihydroxyphenylalanine (L-DOPA) and 5-hydroxytryptophan (5-HTP). Without neuronal dopamine, patients suffer from movement disorders including hypokinesia, dystonia, and oculogyric crisis that result in motor dysfunction, along with behavioral problems, autonomic dysfunction, and developmental delay.

Gene therapy approaches targeting AADC have been developed and are currently under clinical investigation. This is a pharmaceutical/gene therapy application rather than a dietary supplement application, but it illustrates the fundamental importance of this enzymatic pathway.

5.3 Cardiovascular Health — Blood Pressure (GAD/GABA Pathway)

GABA, the direct product of glutamate decarboxylase, has been studied extensively in clinical studies for different applications including treatment of insomnia, high blood pressure, and stress and as an ergogenic substance to increase growth hormone (GH).

Human clinical evidence: The most rigorous human trial in this area was a randomized, placebo-controlled, single-blind trial conducted at the Cardiovascular Disease Center, Tokyo Metropolitan Police Hospital in Japan, which enrolled a total of 39 participants diagnosed with mild hypertension comprising 16 women and 23 men, with an age range of 28–81 years (mean age 54.2 years). The intervention involved a 12-week period during which participants were randomly assigned to daily intake of either fermented milk containing GABA or a placebo, followed by 2 weeks of no intake. Patients received 100 mL of fermented milk daily containing 10–12 mg of GABA for 12 weeks or 100 mL of placebo.

A second controlled study found mixed results: in a placebo-controlled, double-blind study, the effect of fermented milk containing GABA (prepared using L. casei and L. lactis) was studied in 86 healthy subjects with mild or moderate hypertension. Participants received either 100 mL of plain skim powdered milk or fermented milk providing 10 mg of GABA daily (0.15 mg/kg body weight/day) every morning for 12 weeks. All parameters were unremarkable except for blood pressure, which remained slightly elevated in both groups; however, the average systolic and diastolic blood pressures were slightly but significantly higher in the GABA group by approximately 5% compared to controls.

Evidence strength: Most identified studies examined the effect of GABA on mild hypertension; in total, 16 studies were identified that investigated the effect of orally administered GABA as a supplement or in complex matrices on high blood pressure. Evidence is preliminary and mixed. Individual trials suggest modest blood-pressure-lowering effects in mildly hypertensive populations, but results are inconsistent across studies. Many trials are small, of short duration, and conducted with GABA-enriched fermented food matrices that contain multiple potentially bioactive components, making it difficult to attribute effects solely to GABA or to glutamate decarboxylase activity.

5.4 Metabolic Health — Type 1 Diabetes (GAD Pathway)

Injections with GAD65 in ways that induce immune tolerance have been shown to prevent type 1 diabetes in rodent models. In clinical trials, injections with GAD65 have been shown to preserve some insulin production for 30 months in humans with type 1 diabetes. A Cochrane systematic review examined one study showing improvement of C-peptide levels in cases of Latent Autoimmune Diabetes in adults five years following treatment with GAD65. However, it is important to highlight that the studies available were considered to present considerable flaws in quality and design.

In children with new-onset type 1 diabetes, low-dose, twice-daily oral GABA, with or without GAD-alum antigen stimulation, inhibited glucagon and reduced Th1 inflammatory cytokine release. Taken together, these studies support a unique role for GABA as a naturally derived oral agent with multifarious anti-diabetic actions.

Evidence strength: Preliminary; largely derived from rodent models or small human studies. GAD65 antibodies are a recognized autoimmune marker in type 1 diabetes, but use of GAD as a supplemental intervention in humans remains investigational and is not a current clinical standard of care.

5.5 Neuropsychiatric Applications — Stress, Sleep, and Mood

GABA, as a therapeutic supplement, is primarily proposed for managing hypertension, although it has also been associated with potential benefits for anxiety, insomnia, stress, task performance, and exercise recovery.

GABA is still sometimes recommended for the treatment of anxiety and insomnia, but evidence is weak for these purposes when GABA is taken as a standard oral supplement. A mechanistic concern exists: animal studies provide some evidence that small amounts of GABA can cross the blood-brain barrier, but there is a lack of human data to support the role of transporter-mediated GABA entry. This raises a fundamental pharmacokinetic question about whether oral GABA can act centrally at supplemental doses.

Evidence strength: Weak for psychiatric indications (anxiety, insomnia) via standard oral supplementation, primarily because of limited blood-brain barrier penetration data in humans. Research using GABA-enriched fermented foods or biosynthetic "PharmaGABA" formulations is more active but remains in early stages.

5.6 Cancer Biology — Ornithine Decarboxylase

ODC and polyamine metabolism represent an area of intense pharmacological research, particularly in oncology. Ornithine decarboxylase, a key enzyme in polyamine biosynthesis, is often overexpressed in cancers and contributes to polyamine-induced cell proliferation. Expression of ODC1 has been confirmed broadly in endometrial cancer, with highest expression in non-endometrioid, high-grade, and copy-number-high cancers, which have the worst clinical outcomes. ODC1 expression was associated with worse overall survival and increased recurrence in three endometrial cancer gene expression datasets.

The ODC inhibitor difluoromethylornithine (DFMO) is being studied pharmaceutically; treatment with the ODC inhibitor DFMO sensitized triple-negative breast cancer (TNBC) cells to chemotherapy, though this was not observed in receptor-positive breast cancer cells. TNBC cell lines had greater sensitivity to single-agent DFMO, and ODC levels were elevated in TNBC patient samples, suggesting that ODC may be a targetable metabolic vulnerability in TNBC.

Evidence strength: Preclinical (in vitro and animal). This is a pharmaceutical research area, not a dietary supplement application. No clinical evidence supports supplementing ODC activity as a health intervention; the research direction is toward inhibiting ODC in disease states.

5.7 Pyridoxine Supplementation and Decarboxylase Activity

Since all major amino acid decarboxylases require PLP as a cofactor, vitamin B6 status directly modulates the activity of AADC, GAD, and other decarboxylases. Research has demonstrated the direct relationship: the GAD produced in media supplemented with 0.05 mM soluble vitamin B6 analog pyridoxine hydrochloride had activity 1.8-fold higher than that of GAD obtained without supplementation. Purified enzyme exhibited increased activity (1.5-fold higher), superior thermostability (2.8-fold greater), and higher catalytic efficiency (1.6-fold higher).

PLP's participation in actions beyond its coenzymatic function has been extensively investigated in regard to L-amino acid decarboxylase activity. It has been demonstrated that PLP interacts with transcription factors, is involved in AADC folding, dimerization, and splicing, and may prevent the degradation of some PLP-dependent enzymes.

6. Body Systems and Health Areas

Decarboxylase enzymes are relevant to the following body systems and health domains:

Central Nervous System: Dopamine and serotonin synthesis (via AADC); GABAergic neurotransmission (via GAD); histaminergic neurotransmission (via HDC). The clinical features of AADC deficiency are caused by a severe combined deficiency of dopamine, serotonin, epinephrine, and norepinephrine.
Cardiovascular System: GABA modulates blood pressure regulation; GABA is of interest for the induction of hypotension and because of its cholesterol-lowering effect.
Endocrine and Metabolic: GAD65 is a key autoantigen in type 1 diabetes; it has been shown that GABA could prevent obesity by ameliorating oxidative stress in high-fat diet-fed mice, and that it can effectively prevent diabetic conditions by acting as an insulin secretagogue. (Note: these are animal findings.)
Immune System: GAD65 autoantibodies are central to type 1 diabetes pathogenesis; histamine from HDC plays a key role in allergic and inflammatory responses.
Gastrointestinal System: Histidine decarboxylase in parietal cells contributes to gastric acid secretion. GABA-producing gut bacteria influence the gut-brain axis.
Oncology: ODC overexpression is associated with cancer cell proliferation and tumor growth, making it a drug target rather than a supplementation target.
Food Safety: when fish are subjected to temperature abuse during and/or after harvest, bacterial decarboxylation of histidine leads to histamine formation. Other biogenic amines produced during bacterial growth in fish may potentiate histamine's effect.

7. Dosage Forms and Dosages Reported in Studies

The following dosages are sourced directly from published clinical trials and regulatory safety reviews. No inferred or extrapolated dosages are presented.

GABA (Product of Glutamate Decarboxylase)

Data showed no serious adverse events associated with GABA at intakes up to 18 g/day for 4 days and in longer studies at intakes of 120 mg/day for 12 weeks.
In the Inoue et al. trial, patients received 100 mL of fermented milk daily containing 10–12 mg of GABA for 12 weeks.
In the 86-subject double-blind study, participants received fermented milk providing 10 mg of GABA daily (0.15 mg/kg body weight/day) every morning for 12 weeks.

Mucuna pruriens (L-Dopa Substrate Source)

Patients in the Katzenschlager et al. crossover trial were challenged with single doses of 200/50 mg L-dopa/carbidopa and 15 g and 30 g of mucuna preparation in randomized order at weekly intervals.

Pyridoxal 5'-Phosphate (Decarboxylase Cofactor)

In a pediatric case series evaluating PLP supplementation in epilepsy related to PLP-dependent enzyme disorders, a response to PLP supplementation was initially positive in 5 cases at 10–30 mg/kg/day.

8. Safety Considerations and Interactions

8.1 GABA Safety

The U.S. Pharmacopeia (USP) conducted a comprehensive safety evaluation of GABA by assessing clinical studies, adverse event information, and toxicology data. Clinical studies investigated the effect of pure GABA as a dietary supplement or as a natural constituent of fermented milk or soy matrices. Data showed no serious adverse events associated with GABA at intakes up to 18 g/day for 4 days and in longer studies at intakes of 120 mg/day for 12 weeks. Some studies showed that GABA was associated with a transient and moderate drop in blood pressure (less than 10% change).

It is possible that using GABA concurrently with antihypertensive drugs could raise the risk of hypotension, because GABA may cause a drop in blood pressure.

GABA's ability to suppress T-lymphocyte proliferation and cytokine production via GABA-A receptors raises a theoretical concern about additive immunosuppression when combined with immunosuppressive drugs. This has not been clinically studied but warrants awareness.

8.2 Mucuna pruriens / L-Dopa and AADC Inhibitors

AADC is inhibited by carbidopa outside of the blood-brain barrier to inhibit the premature conversion of L-DOPA to dopamine in the treatment of Parkinson's disease. Persons taking pharmaceutical carbidopa-levodopa (Sinemet) should be aware that concurrent ingestion of Mucuna pruriens supplements introduces additional L-dopa without a matched peripheral decarboxylase inhibitor, potentially affecting dopamine levels and drug pharmacokinetics.

Levodopa in combination with carbidopa is avoided in AADC enzyme deficiency because carbidopa inhibits the AADC enzyme. This illustrates the importance of the decarboxylase pathway context when evaluating drug-supplement interactions.

8.3 Vitamin B6 Toxicity and Decarboxylase Function

Vitamin B6 is unique in that either deficiency or excess can cause peripheral neuropathy. Since PLP/vitamin B6 is a required cofactor for decarboxylase activity, both inadequate and excessive supplementation carry risks. Deficiency impairs decarboxylase activity and neurotransmitter synthesis; excess (especially from pyridoxine supplements) causes sensory neuropathy.

8.4 Histidine Decarboxylase and Food Safety

Under inappropriate storage conditions, such as at temperatures above 4°C and at pH values ranging from 4.0 to 5.0, histidine decarboxylase exhibits greater activity and bacteria reproduce faster, thus increasing the risk of histamine formation. Histamine is a food allergen, and high histamine intake in humans can cause food poisoning. When present at higher levels, histamine can be a health hazard. It can cause nausea, vomiting, cramps, burning sensation in mouth, itching, urticaria, facial swelling, and intense headache. Other biogenic amines such as tyramine, cadaverine, and putrescine, often formed in a similar manner in foods, may possibly enhance this toxicity.

8.5 Antiepileptic Drug Interactions (GABA)

Given that GABA supplementation has been studied (and found largely ineffective) in epilepsy, patients on antiepileptic medications should not use GABA supplements without medical supervision. There is no evidence that GABA supplements enhance the efficacy of antiepileptic drugs, and they could potentially confound treatment monitoring.

9. Current State of Evidence and Research Limitations

Some studies suggest that supporting natural decarboxylase activity—either through diet or supplementation—may contribute to improved neurotransmitter synthesis and metabolic balance. However, the scientific community acknowledges that more clinical research is needed to fully validate the specific effects and safety of decarboxylase supplementation in humans.

The fundamental challenge in evaluating "decarboxylase supplementation" is that decarboxylase enzymes themselves are endogenous proteins that cannot be directly and meaningfully supplemented as such — oral protein enzymes are digested before they can act systemically. The practical applications are therefore: (1) providing substrates (L-dopa, 5-HTP, L-glutamate) that decarboxylase enzymes act upon; (2) providing the PLP cofactor (vitamin B6) required for decarboxylase activity; or (3) consuming the decarboxylase products directly (e.g., GABA). Each approach carries its own evidence base, most of which remains preliminary or limited in human clinical scope.

References

Health Conditions

Health conditions that Decarboxylase may help support.

No conditions available.

Body Systems

Body systems that Decarboxylase may help support.

No body systems available.